Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Current Status and Future Applications

Allan J. Pantuck, George Thomas, Arie S. Belldegrun, Robert A. Figlin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and increasing evidence suggests its dysregulation in cancer. Receiving input from multiple signals, including growth factors, hormones, nutrients, and other stimulants or mitogens, the pathway stimulates protein synthesis by phosphorylating key translation regulators such as ribosomal S6 kinase. The mTOR pathway also contributes to many other critical cellular functions, including protein degradation and angiogenesis. Hence, use of inhibitors of the pathway represents a new strategy for the targeted treatment of RCC, and mTOR inhibitors have already shown promising clinical efficacy and low toxicity profiles in unselected patients with metastatic RCC. As with other new, targeted cancer agents, the future use of mTOR inhibitors will benefit from reproducible biomarkers that can be used in the clinic to identify patients most likely to respond and to document modulation of the drug target in addition to clinical response.

Original languageEnglish (US)
Pages (from-to)607-613
Number of pages7
JournalSeminars in Oncology
Volume33
Issue number5
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Sirolimus
Renal Cell Carcinoma
Ribosomal Protein S6 Kinases
1-Phosphatidylinositol 4-Kinase
Mitogens
Proteolysis
Growth Hormone
Neoplasms
Intercellular Signaling Peptides and Proteins
Biomarkers
Food
Growth
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma : Current Status and Future Applications. / Pantuck, Allan J.; Thomas, George; Belldegrun, Arie S.; Figlin, Robert A.

In: Seminars in Oncology, Vol. 33, No. 5, 10.2006, p. 607-613.

Research output: Contribution to journalArticle

Pantuck, Allan J. ; Thomas, George ; Belldegrun, Arie S. ; Figlin, Robert A. / Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma : Current Status and Future Applications. In: Seminars in Oncology. 2006 ; Vol. 33, No. 5. pp. 607-613.
@article{2cc52730f0624192a985f926fec73a69,
title = "Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Current Status and Future Applications",
abstract = "Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and increasing evidence suggests its dysregulation in cancer. Receiving input from multiple signals, including growth factors, hormones, nutrients, and other stimulants or mitogens, the pathway stimulates protein synthesis by phosphorylating key translation regulators such as ribosomal S6 kinase. The mTOR pathway also contributes to many other critical cellular functions, including protein degradation and angiogenesis. Hence, use of inhibitors of the pathway represents a new strategy for the targeted treatment of RCC, and mTOR inhibitors have already shown promising clinical efficacy and low toxicity profiles in unselected patients with metastatic RCC. As with other new, targeted cancer agents, the future use of mTOR inhibitors will benefit from reproducible biomarkers that can be used in the clinic to identify patients most likely to respond and to document modulation of the drug target in addition to clinical response.",
author = "Pantuck, {Allan J.} and George Thomas and Belldegrun, {Arie S.} and Figlin, {Robert A.}",
year = "2006",
month = "10",
doi = "10.1053/j.seminoncol.2006.06.002",
language = "English (US)",
volume = "33",
pages = "607--613",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma

T2 - Current Status and Future Applications

AU - Pantuck, Allan J.

AU - Thomas, George

AU - Belldegrun, Arie S.

AU - Figlin, Robert A.

PY - 2006/10

Y1 - 2006/10

N2 - Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and increasing evidence suggests its dysregulation in cancer. Receiving input from multiple signals, including growth factors, hormones, nutrients, and other stimulants or mitogens, the pathway stimulates protein synthesis by phosphorylating key translation regulators such as ribosomal S6 kinase. The mTOR pathway also contributes to many other critical cellular functions, including protein degradation and angiogenesis. Hence, use of inhibitors of the pathway represents a new strategy for the targeted treatment of RCC, and mTOR inhibitors have already shown promising clinical efficacy and low toxicity profiles in unselected patients with metastatic RCC. As with other new, targeted cancer agents, the future use of mTOR inhibitors will benefit from reproducible biomarkers that can be used in the clinic to identify patients most likely to respond and to document modulation of the drug target in addition to clinical response.

AB - Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and increasing evidence suggests its dysregulation in cancer. Receiving input from multiple signals, including growth factors, hormones, nutrients, and other stimulants or mitogens, the pathway stimulates protein synthesis by phosphorylating key translation regulators such as ribosomal S6 kinase. The mTOR pathway also contributes to many other critical cellular functions, including protein degradation and angiogenesis. Hence, use of inhibitors of the pathway represents a new strategy for the targeted treatment of RCC, and mTOR inhibitors have already shown promising clinical efficacy and low toxicity profiles in unselected patients with metastatic RCC. As with other new, targeted cancer agents, the future use of mTOR inhibitors will benefit from reproducible biomarkers that can be used in the clinic to identify patients most likely to respond and to document modulation of the drug target in addition to clinical response.

UR - http://www.scopus.com/inward/record.url?scp=33749642343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749642343&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2006.06.002

DO - 10.1053/j.seminoncol.2006.06.002

M3 - Article

C2 - 17045090

AN - SCOPUS:33749642343

VL - 33

SP - 607

EP - 613

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5

ER -